ASND vs ZBH
Ascendis Pharma A/S vs Zimmer Biomet — AI-powered side-by-side comparison
ASND
Ascendis Pharma A/S
66
Buy
VS
| Metric | ASND | ZBH |
|---|
| AI Score |
66
|
69
|
| Price |
$254.27
|
$97.22
|
| P/E Ratio |
26.92×
|
23.54×
|
| ROE |
134.6%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
88.2%
|
69.9%
|
| Debt / Equity |
1.84×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
56.3
|
63.1
|
| Beta |
0.382
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for ASND versus ZBH.
ZBH leads by 3 points.
ZBH scores 69/100 (Buy) versus ASND at 66/100 (Buy).
ASND Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 129.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 134.8% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 27.9 is moderate-to-rich — Value
- Price-to-book of 22.5x prices in significant intangible value — Value
- Debt-to-equity of 1.93 adds balance-sheet risk to the value case — Value
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical